This article aims to elucidate the rationale for utilizing BMD, CTX-1, and osteocalcin as monitoring parameters for bone remodeling in CML patients treated with Imatinib. The gene discussed is BGLAP; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.